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Abstract
The first total synthesis of leopolic acid A, a fungal metabolite with a rare 2,3-pyrrolidinedione nucleus linked to an ureido dipep-
tide, was designed and carried out. Crucial steps for the strategy include a Dieckmann cyclization to obtain the 2,3-pyrrolidine-
dione ring and a Wittig olefination to install the polymethylene chain. An oxazolidinone-containing leopolic acid A analogue was
also synthesized. The antibacterial activity showed by both compounds suggests that they could be considered as promising candi-
dates for future developments.
Introduction
Great concern has recently been expressed about the dimin-
ishing efficacy of current antibiotic therapies and the emer-
gence of multidrug resistant strains. Novel potent compounds
endowed with new mechanisms of action are urgently needed.
In this regard, natural products continue to be a rich source of
biologically validated structures, which can be modified and op-
timized in drug discovery [1].
Chemical analysis of a terrestrial-derived Streptomyces sp. iso-
lated from the rhizosphere of the plant Juniperus excelsa
yielded a new metabolite, leopolic acid A (1, Figure 1) [2].
Leopolic acid has unprecedented structural features consisting
of an aliphatic side chain attached to a 2,3-pyrrolidinedione
residue, which in turn, is connected to the ureido dipeptide
L-Phe-L-Val. The compound showed antifungal and antibacte-
rial activity against Mucor hiemalis and Staphylococcus aureus
with a MIC of 32 and 16 μg/mL, respectively [2].
Compounds containing the isomeric 2,4-pyrrolidinedione ring
system (tetramic acids) are widespread among the fungal
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Scheme 1: Synthesis of leopolic acid A. Reagents and conditions: a) p-methoxybenzylamine, EtOH, rt, 12 h, 98%; b) diethyl oxalate, NaOEt, EtOH,
reflux, 3 h, 83%; c) BnBr, K2CO3, DMF, 0 °C to rt, 1 h, 50%; d) DIBAL-H, CH2Cl2, −78 °C, 2 h, 56%; e) PPh3, CBr4, CH2Cl2, rt, 5 h, 52%; f) PPh3,
toluene, reflux, 5 h, 75%; g) n-nonanal, LiHMDS, THF, −78 °C to rt, 5 h, 52%; h) CAN, CH3CN:H2O, 0 °C to rt, 3 h, 73%; i) 2-tert-butoxycarbonyl-
amino-3-methylbutyric acid pentafluorophenyl ester, n-BuLi, THF, −78 °C, 0.5 h, 71%; j) DIBAL-H, CH2Cl2, −78 °C, 2 h, 30%; k) PCC, CH2Cl2, 0 °C to
rt, 12 h, 46%; l) n-nonyltriphenylphosphonium bromide, n-BuLi, THF, −78 °C to 0 °C, 2 h; m) TFA, CH2Cl2, 0 °C to rt, 1 h; n) L-phenylalanine benzyl
ester DIEA, triphosgene, CH2Cl2, rt, 1 h, 60% over three steps; o) H2, Pd/C, EtOAc, rt, 2 h, 77%.
Figure 1: Structure of leopolic acid A.
metabolites and show a number of biological activities, i.e.,
antibacterial, antiviral, antifungal and anticancer. More than one
hundred of them have been isolated from a variety of natural
sources [3].
Conversely, natural compounds with a simple 2,3-pyrrrolidine-
dione nucleus are indeed very few [4-6]. Even though this core
can be considered an attractive target, synthetic studies directed
to find new biologically active compounds are scarce as well
[7-9].
The unique structure and bioactivity of leopolic acid prompted
us to plan a synthesis which might be used in the preparation of
various analogues. A retrosynthetic disconnection of 1 at the
amide bond gave two fragments, the ureido dipeptide L-Phe-L-
Val and 4-decyl-3-hydroxy-1,5-dihydropyrrol-2-one, which
appeared well suited for a convergent synthetic approach
(Figure 1).
Results and Discussion
A straightforward route to the intriguing 2,3-pyrrolidinedione
system appeared to be the Michael addition of a suitable amine
to ethyl acrylate, followed by a Dieckmann cyclization with
diethyl oxalate [10,11]. We chose the p-methoxybenzyl (PMB)
protecting group for the amine, because of its facile cleavage
with cerium ammonium nitrate (CAN) or 2,3-dichloro-5,6-
dicyanobenzoquinone (DDQ). Thus, 2,3-pyrrolidinedione 3 was
obtained by the reaction of ethyl acrylate with p-methoxy-
benzylamine, followed by treatment with diethyl oxalate
(Scheme 1) [12]. On the basis of NMR data, the compound
exists as an enol tautomer (see Supporting Information File 1).
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Indeed, perusal of the literature indicated that apparently all
4-monosubstituted 2,3-pyrrolidinediones are highly enolized
[13-15]. Protection of the enolic OH with a benzyl group, using
BnBr and K2CO3, gave compound 4. The reduction of 4 with
DIBAL-H gave the corresponding primary alcohol, which was
converted into bromide 5 by Appel reaction with PPh3 and
CBr4. The phosphonium salt obtained from this bromide was
subjected to a Wittig reaction with nonanal, to afford com-
pound 6 [12].
Attempts to remove the PMB protecting group (CAN, DDQ,
TFA or hydrogenation) from 6 or from the intermediate alcohol
and bromide resulted in the decomposition of the products. The
instability of these and other derivatives of the N-unsubstituted
ring, already observed by others [11], made the synthetic task
more troublesome than expected.
The NH-free pyrrolidinedione scaffold was found to be stable
only in the presence of the ester group in position 4. In fact, a
deprotected compound 7 could only be obtained by treatment of
4 with CAN.
This result prompted us to install the amino acid fragment on
compound 7 before constructing the chain in position 4, so that
it could also act as a NH-protecting group in the following
steps. However, as the ureido fragment would interfere with the
reduction of the ester group on the nucleus, we opted for
installing sequentially the valine, then the phenylalanine
residue.
Thus, compound 7 was coupled with pentafluorophenyl ester-
activated N-Boc-valine to obtain compound 8 (Scheme 1).
Treatment with DIBAL-H led to the reduction of both the ester
and the CO group of the valine moiety (9). Compound 9 was
obtained as a 9:1 mixture of diastereomers, the syn (S,S) dia-
stereomer being the major one. The selectivity of the reduction
is in agreement with previous results and is consistent with the
Cram model for a chelation controlled reduction [16-18]. Both
OH groups of compound 9 were oxidized by PCC to obtain
aldehyde 10. The long carbon chain was incorporated into 10 by
Wittig olefination with n-nonyltriphenylphosphonium bromide
and n-BuLi at −78 °C (11). Deprotection and treatment with
triphosgene and phenylalanine benzyl ester at rt allowed the for-
mation of compound 13. Finally, catalytic hydrogenation
afforded the desired leopolic acid A (1), whose spectroscopic
data completely matched with those reported in the literature [1]
(see Supporting Information File 2 for NMR spectra).
Interestingly, while searching the best conditions to obtain com-
pound 10, we treated 9 with oxalyl chloride and DMSO,
following the Swern protocol [19]. This treatment led to the for-
mation of the oxazolidinone 14 (Scheme 2). We assume that the
reaction occurred via inversion of the configuration at the
hydroxylated carbon, based on an intramolecular SN2 cyclocar-
bamation by the Boc group [20,21]. The small coupling con-
stant (J = 2.6 Hz) between the two hydrogens on the oxazolidi-
none ring confirmed that the compound was the anti derivative
[16,17,22,23].
Scheme 2: Synthesis of compound 17. Reagents and conditions:
a) Oxalyl chloride, DMSO, CH2Cl2, TEA, −78 °C to 0 °C, 2 h, 60%;
b) n-nonyltriphenylphosphonium bromide, n-BuLi, THF, −78 °C to 0 °C,
2 h, 74%; c) L-phenylalanine benzyl ester, DIEA, triphosgene, CH2Cl2,
rt, 72 h, 49%; d) H2, Pd/C, EtOAc, rt, 2 h, 50%.
The oxazolidinone ring is rare among natural products, but there
are successful examples in medicinal chemistry of drugs con-
taining this skeleton, such as the antibiotic linezolid [24].
As the core structure of compound 14 represents a new scaffold,
never isolated or synthesized before, we decided to incorporate
the structural features found in leopolic acid into this novel
heterocyclic system. Accordingly, Wittig olefination of 14, fol-
lowed by coupling with L-phenylalanine benzyl ester, and
subsequent catalytic hydrogenation in EtOAc of 16 afforded the
analogue of leopolic acid 17 in 50% yield.
Compounds 1 and 17 were subjected to a preliminary study of
the antimicrobial activity against Staphylococcus and
Escherichia coli (Staphylococcus pseudintermedius [25],
25 strains; Escherichia coli, 20 strains. QC: S. aureus ATCC
Beilstein J. Org. Chem. 2016, 12, 1624–1628.
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25923 and Escherichia coli ATCC 25922 were also used, see
Supporting Information File 1 for details). The MIC values of 1
against Staphylococcus pseudintermedius range at 16 µg/mL,
while the values for 17 against Staphylococcus pseudinter-
medius are more variable and range between 32 and 64 µg/mL.
The MIC of 1 and 17 against Escherichia coli range at
128 µg/mL for both molecules (see Supporting Information
File 2 for details). The antibacterial activity shown by both
compounds suggests that they can be considered as promising
candidates for further developments.
Conclusion
In conclusion, leopolic acid A was obtained for the first time in
a 11-step synthesis. The main difficulty encountered was the
instability of a number of intermediates containing the 2,3-
pyrrolidinedione moiety, which may be a reason for the scarce
presence of similar compounds in the literature. With these
results, we have attained a deeper knowledge of the chemistry
of the unusual 2,3-pyrrolidinedione system and developed a
synthetic strategy towards new lead compounds with antimicro-
bial activity. Efforts to synthesize analogues to build a struc-
ture–activity relationship (SAR) profile and optimize the activi-
ty are underway.
Supporting Information
Supporting Information File 1
General experimental methods, synthetic procedures and
analytical data for the reported compounds; antimicrobial
activity evaluation procedures.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-12-159-S1.pdf]
Supporting Information File 2
1H and 13C NMR spectra of all the new compounds; 2D
HMBC, HSQC spectra of compounds 1, and 17, COSY
spectrum of compound 1, MIC of compounds 1 and 17
against Staphylococcus pseudintermedius and Escherichia
coli strains.
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